These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36967432)

  • 1. The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients.
    Wang J; Bao J; Wang R; Hong J; Zhang L; Que Q; Xu S; Wu Y; Zhan Q; Liu Y; Liu J; Zheng S; Ling S; Xu X
    World J Surg Oncol; 2023 Mar; 21(1):104. PubMed ID: 36967432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
    Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
    Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
    Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G
    JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological differentiation predicts post-liver transplantation survival time.
    Li WX; Li Z; Gao PJ; Gao J; Zhu JY
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
    Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
    JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
    Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
    Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
    Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.
    Mahmud N; John B; Taddei TH; Goldberg DS
    Clin Transplant; 2019 Jul; 33(7):e13634. PubMed ID: 31177570
    [TBL] [Abstract][Full Text] [Related]  

  • 14.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant.
    Sarkar M; Dodge JL; Roberts JP; Terrault N; Yao F; Mehta N
    Ann Hepatol; 2016; 15(4):545-9. PubMed ID: 27236153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant inflammatory cytokine signature adds value for predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.
    Ng KT; Liu J; Yeung OW; Pang L; Shiu HC; Liu H; Yang XX; Chan AC; Wong TC; Lo CM; Man K
    Hepatol Int; 2023 Dec; 17(6):1596-1609. PubMed ID: 37542605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFP-Score.
    Menahem B; Duvoux C; Ganne N; Mallat A; Seror O; Calderaro J; Launoy G; Alves A; Cherqui D; Luciani A; Laurent A
    World J Surg; 2019 Jan; 43(1):221-229. PubMed ID: 30128773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    Cucchetti A; Serenari M; Sposito C; Di Sandro S; Mosconi C; Vicentin I; Garanzini E; Mazzaferro V; De Carlis L; Golfieri R; Spreafico C; Vanzulli A; Buscemi V; Ravaioli M; Ercolani G; Pinna AD; Cescon M
    J Hepatol; 2020 Aug; 73(2):342-348. PubMed ID: 32201284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
    Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
    United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.